Results of clinical trials, assessing the efficacy and safety of bardoxolone as a nephroprotective agent are discussed.
Обсуждаются результаты клинических исследований, в которых была оценена способность бардоксолона замедлять темп падения СКФ.
bardoxoloneglomerular filtration ratediabetic nephropathyбардоксолонСКФдиабетическая нефропатияWardle E.N. Cellular oxidative processes in relation to renal diseases. Am J Nephrol. 2005; 25(1): 13-22.Rojas-Rivera J., Ortiz A., Egido A. Antioxidants in kidney disease. The impact of bardoxolone methyl. Int J Nephrol. 2012; doi: 10.1155/2012/321714 doi: 10.1155/2012/321714 клиническая нефрология З - 2013Lazaro A., Gallego-Delgado P., Justo P. et al. Long-term blood pressure control prevents oxidative renal injury. Antioxidants and Redox Signalling. 2005; 7(9-10): 1285-1293.Lee H.B., Yu M.R., Yang Y. et al. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol. 2003; 14 (8 Suppl 3): S241-S245.Budislavjevic M.N., Hodge L., Barber K. et al. Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis. Am J Physiol. 2003; 285(6): F1138-F1148.Foster M.H. T-cells and B-cells in lupus nephritis. Semin Nephrol. 2007; 27(1): 47-58.Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414 (6865): 813-820.Jaiswal A.K. Nrf2 signalling in coordinated activation of antioxidant gene expression. Free Radic Biol Med. 2004; 36(10): 1199-1207.Unzgwari Z., Bailey-Downs L., Gautam T. et al. Adaptive induction NF E2-derived factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia. Am J Physiol Heart Circ Physiol. 2011; 300(4): H1133-H1140.Thomas M.C. Bardoxolone: augmenting the Yin in chronic kidney disease. Diab Vasc Dis Res. 2011; 8(4): 303-304.Kim S.B., Pandita R.K., Eskiocak U. et al. Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation. Proc Natl Acad Sci U S A. 2012; 109(43): E2949-2955.Meyer C. Bardoxolone, a novel oral anti-inflammatory agent shown to improve renal function. Nationa Kidney Foundation Spring Clinical Meeting 2009 (abstr).Pergola P.E., Krauth M., Huff J.W. et al. Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol. 2011; 33(5): 469-476.Warnock D.G., Hebbar S., Bargman J. et al. Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis. Contrib Nephrol. 2012; 178: 157-163.Ding Y., Stidham R.D., Bumeister R. et al. The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int. 2012 Dec 12. doi: 10.1038/ki.2012.393. [Epub ahead of print].Wu Q.Q., Wang Y., Senitko M. et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARy, and HO-1. Am J Physiol Renal Physiol. 2011; 300(5): F1180-F1192.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1-150Reisman S.A., Chertow G.M., Hebbar S. et al. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol. 2012; 23(10): 1663-1673.Pergola P.E., Raskin P., Toto R.D. et al. for BEAM Study Investigators. Bardoxolone methyl and kidney function in type 2 diabetes. N Engl J Med 2011; 365: 327-336.Jun M., Venkataraman V., Razavian M. et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev. 2012; 10: CD008176. doi: 10.1002/14651858.CD008176.pub2.